Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.
USD 29.95
Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.

Contact Information

Headquarters
Blvd. Quilin 5273, Penalolen
Santiago; Metropolitana; Map
Tel: +56 2 594
Email: @andromaco.cl
Website: http://www.laboratoriosandromaco.cl

Full name: Laboratorios Andromaco S.A.

Status: Listed
Legal Form: Public Limited Company
Operational Status: Operational
EMISid: 1160748
CL-RUT: 924480009
Incorporation Date: 16-Dec-64

Main Activities

Main Activities: Pharmaceutical and Medicine Manufacturing

Main Products

Medicines

Company Description

Marketing and production of drugs of excellent quality and efficiency. The company represents important international pharmaceuticals firms, through which it incorporates exclusive and innovative products to its offer, for disease prevention and treatment. In addition, AndrĂ³maco plays an active role contributing to generate pharmaceutical knowledge trough the research and development of vanguard products. The company is formed by Laboratorios AndrĂ³maco S.A., Laboratorios Silesia S.A., ABL Pharma,…

More

Basic Information

Total Employees:
()
Outstanding Shares:
: ()
Financial Auditors:
()

EMIS Benchmark Score

View all parameters in Benchmark Score

Quote Chart

Quote Summary

Last Price 310.00
Volume 1,763,000
Turnover 550,056,000
Index
Market Electronic Stock Exchange
Ticker ANDROMACO
Market Cap Market Cap 186,368,539
52 Week High 310.00
52 Week Low 229.50
Price to Earnings (P/E) -404.95
Earnings per Share (EPS) -0.82
Dividend Yield 0.5 (October 16, 2012)
Bookvalue 31,149,343
Enterprise Value 223,498,490
Quote updated on October 11, 2013
Note: data in CLP Thousands.

Key Executives

President of the Board of Directors
More

Ownership Details

Inversiones Gruchi Limitada
81.59%
More

Key Stats

Select Items to chart them. 2014 Q1
Net sales revenue
Total operating revenue
Operating profit (EBIT)
EBITDA
Net Profit (Loss) for the Period
Total assets 115,241,080
Total equity
Operating Profit (EBIT) Margin
Return on Sales (ROS)
Return on Equity (ROE)
Debt to Equity
Quick Ratio
Cash Ratio
Note: units in Thousands. Statement: Audited, Consolidated
Source: Superintendencia de Valores y Seguros, EMIS Company Database.

Financials

Competitors - Chile

CLP | USD | EUR

EMIS DealWatch Deals

DealMonitor Deal Intents

for 29.95 USD
Payment methods include:
USD 29.95
Most recent financial data: 2013
Payment methods include:
The full PDF report for this company will be available to download immediately after purchase. The report will contain:
Company Tear Sheet
Contact Information
NAICS Industry Classification
Business description
Basic Information
Share Price information
Key Executives
Ownership Details
Subsidiaries and Affiliates
Key Financial Highlights
Financial Performance Charts
Latest M&A and ECM Deals
Top Competitors
Financial Statements
Annual Statements
Ratios
EMIS Credit Analytics
EMIS Benchmark Score

- or -

EMIS company profiles are part of a larger information service that combines company, industry and country data and analysis for over 120 emerging markets on a unique information platform.

If you need broad and deep coverage of one or many countries, you may be interested in subscribing. Request a demonstration of our full service and one of our account managers will be in touch.

Register Your Interest